Mankind Pharma Ltd. (MANKIND) fundamentals
Mankind Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MANKIND (ISIN INE634S01028). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Mankind Pharma Ltd. does
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
Valuation and market data
| Last close | ₹2312.00 |
|---|---|
| Market capitalisation | ₹96,675 crore |
| Enterprise value | ₹1.01 lakh crore |
| P/E (TTM) | 49.88 |
| Price to book | 5.84 |
| Price to sales (TTM) | 3.75 |
| Book value per share | ₹396.06 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue May 09 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹10,747 crore | ₹2,315 crore | ₹2,038 crore | 49.37 |
| Mar 2025 | ₹10,001 crore | ₹2,147 crore | ₹1,725 crore | 44.22 |
| Mar 2024 | ₹8,900 crore | ₹2,185 crore | ₹1,773 crore | 46.84 |
| Mar 2023 | ₹8,290 crore | ₹1,563 crore | ₹1,248 crore | 31.16 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 72.6% |
|---|---|
| Foreign institutions (FII) | 9.4% |
| Mutual funds | 11.3% |
| Other domestic institutions | 4.3% |
| Retail and others | 2.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.